Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation
- PMID: 11064467
Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation
Abstract
Background and objectives: Leukemia relapse occurring in donor cells after allogeneic hematopoietic stem cell transplantation has been reported in rare cases. Cytogenetic analysis and molecular probing of variable number of tandem repeats (VNTRs) have been used to confirm this unusual event in the few cases so far reported in the literature. The aim of this study was to demonstrate that extensive molecular characterization of leukemic cells at diagnosis and relapse may be necessary to avoid many technical pitfalls possibly leading to an erroneous diagnosis of leukemia relapse in donor cells after allogeneic transplantation.
Design and methods: We report the case of a 49- year old man who received an allogeneic transplantation from his HLA-identical sister because of BCR-ABL+ acute lymphoblastic leukemia (ALL). After having achieved complete hematologic and molecular remission, two years later an overt leukemia relapse occurred with cytogenetic findings suggesting a leukemia relapse in donor cells. The donor or patient origin of leukemic cells at relapse was further investigated by fluorescence in situ hybridization (FISH) karyotyping, reverse transcription (RT) polymerase chain reaction (PCR) analysis of BCR-ABL chimeric transcripts, PCR amplification of several VNTRs and the Y chromosome-specific DYS14 sequence and finally by amplification, cloning and sequencing of the CDRIII region of the immunoglobulin heavy chain (IgH) gene.
Results: At the time of relapse, conventional and FISH karyotyping revealed the presence of a Phl+ chromosome and a female karyotype in all the 25 metaphases analyzed and PCR amplification of the Y chromosome-specific DYS14 sequence was negative. Moreover, the molecular evaluation of hematopoietic chimerism performed by the NZ-22 VNTR allowed us to demonstrate that at the time of relapse, a consistent proportion of hematopoietic cells was of donor origin. However, the molecular cloning and sequencing of the CDRIII region of the immunoglobuin heavy chain (IgH) gene rearrangement in leukemic blasts at diagnosis and relapse demonstrated their identity thus formally proving the patient origin of both leukemic clones.
Interpretation and conclusions: While the simplest interpretation of the apparent female karyotype at relapse is the consequence of a loss of the Y chromosome which in leukemic blasts took place along with duplication of an X-chromosome, this case strongly emphasizes the need for accurate and extensive molecular characterization to prove the donor origin of a leukemia relapse after allogeneic transplantation.
Similar articles
-
Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.Am J Hematol. 2006 Oct;81(10):735-46. doi: 10.1002/ajh.20693. Am J Hematol. 2006. PMID: 16838323
-
[The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 Apr;22(2):212-5. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005. PMID: 15793790 Chinese.
-
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.Bone Marrow Transplant. 2000 Jun;25(11):1209-11. doi: 10.1038/sj.bmt.1702418. Bone Marrow Transplant. 2000. PMID: 10849535
-
[Acute lymphoblastic leukemia with p190 type bcr/abl chimeric mRNA at relapse].Rinsho Ketsueki. 2002 Sep;43(9):836-40. Rinsho Ketsueki. 2002. PMID: 12412288 Review. Japanese.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
Recurrent disease or donor cell leukemia?: Brain teaser after allogeneic bone marrow transplantation.Chimerism. 2011 Jan;2(1):19-20. doi: 10.4161/chim.2.1.14726. Chimerism. 2011. PMID: 21547032 Free PMC article.
-
Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists.Mol Cytogenet. 2016 Aug 8;9:62. doi: 10.1186/s13039-016-0275-3. eCollection 2016. Mol Cytogenet. 2016. PMID: 27508005 Free PMC article.
-
Lessons Learned from Donor Cell-Derived Myeloid Neoplasms: Report of Three Cases and Review of the Literature.Life (Basel). 2022 Apr 8;12(4):559. doi: 10.3390/life12040559. Life (Basel). 2022. PMID: 35455050 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Research Materials
Miscellaneous